Cargando…

SARS-CoV 2 spike protein S1 subunit as an ideal target for stable vaccines: A bioinformatic study

The Covid-19 a pandemic infectious disease and affected life across the world resulting in over 188.65 million confirmed cases across 223 countries, territories and areas with 4.06 million deaths. It is caused by a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and spike (S) protein of...

Descripción completa

Detalles Bibliográficos
Autores principales: S.N., Nagesha, B.N., Ramesh, C., Pradeep, K.S., Shashidhara, Ramakrishnappa, Thippeswamy, B.T., Krishnaprasad, S.M., Jnanashree, M., Manohar, N., Arunkumar, Yallappa, D., Dhanush Patel, T.V., Rakesh, E., Girish, Bagoji, Mahantesh, Chandaragi, Shreeram S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8279943/
https://www.ncbi.nlm.nih.gov/pubmed/34307057
http://dx.doi.org/10.1016/j.matpr.2021.07.163
_version_ 1783722549193998336
author S.N., Nagesha
B.N., Ramesh
C., Pradeep
K.S., Shashidhara
Ramakrishnappa, Thippeswamy
B.T., Krishnaprasad
S.M., Jnanashree
M., Manohar
N., Arunkumar
Yallappa
D., Dhanush Patel
T.V., Rakesh
E., Girish
Bagoji, Mahantesh
Chandaragi, Shreeram S.
author_facet S.N., Nagesha
B.N., Ramesh
C., Pradeep
K.S., Shashidhara
Ramakrishnappa, Thippeswamy
B.T., Krishnaprasad
S.M., Jnanashree
M., Manohar
N., Arunkumar
Yallappa
D., Dhanush Patel
T.V., Rakesh
E., Girish
Bagoji, Mahantesh
Chandaragi, Shreeram S.
author_sort S.N., Nagesha
collection PubMed
description The Covid-19 a pandemic infectious disease and affected life across the world resulting in over 188.65 million confirmed cases across 223 countries, territories and areas with 4.06 million deaths. It is caused by a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and spike (S) protein of SARS-CoV-2, which plays a key role in the receptor recognition and cell membrane fusion process, is composed of two subunits, S1 and S2. The S1 subunit contains a receptor-binding domain (RBD) that recognizes and binds to the host receptor angiotensin-converting enzyme 2 (ACE2), while the S2 subunit mediates viral cell membrane fusion. Hence, it is a key target for developing neutralizing antibodies. Here, we have performed phylogenetic analysis and structural modeling of the SARS-CoV-2 spike glycoprotein, which is found highly conserved. The overall percent protein sequence identity from the SARS-CoV-2 spike protein sequences from the NCBI database was 99.68%. The functional domains of the S protein reveal that the S1 subunit was highly conserved (99.70%) than the S2 subunit (99.66%). Further, the 319–541 residues (RBD) of amino acids within the S1 domain were 100% similar among the spike protein. The 3D modeling of SARS-CoV-2 spike glycoprotein indicated that S protein has four domains with five protein units and the S1 subunit from 1 to 289 amino acid of domain 1 is highly conserved without any change in the ligand interaction site. This analysis clearly suggests that the S1 subunit (RBD 319–541) can be used as a target region for stable and safe vaccine development.
format Online
Article
Text
id pubmed-8279943
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier Ltd.
record_format MEDLINE/PubMed
spelling pubmed-82799432021-07-20 SARS-CoV 2 spike protein S1 subunit as an ideal target for stable vaccines: A bioinformatic study S.N., Nagesha B.N., Ramesh C., Pradeep K.S., Shashidhara Ramakrishnappa, Thippeswamy B.T., Krishnaprasad S.M., Jnanashree M., Manohar N., Arunkumar Yallappa D., Dhanush Patel T.V., Rakesh E., Girish Bagoji, Mahantesh Chandaragi, Shreeram S. Mater Today Proc Article The Covid-19 a pandemic infectious disease and affected life across the world resulting in over 188.65 million confirmed cases across 223 countries, territories and areas with 4.06 million deaths. It is caused by a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and spike (S) protein of SARS-CoV-2, which plays a key role in the receptor recognition and cell membrane fusion process, is composed of two subunits, S1 and S2. The S1 subunit contains a receptor-binding domain (RBD) that recognizes and binds to the host receptor angiotensin-converting enzyme 2 (ACE2), while the S2 subunit mediates viral cell membrane fusion. Hence, it is a key target for developing neutralizing antibodies. Here, we have performed phylogenetic analysis and structural modeling of the SARS-CoV-2 spike glycoprotein, which is found highly conserved. The overall percent protein sequence identity from the SARS-CoV-2 spike protein sequences from the NCBI database was 99.68%. The functional domains of the S protein reveal that the S1 subunit was highly conserved (99.70%) than the S2 subunit (99.66%). Further, the 319–541 residues (RBD) of amino acids within the S1 domain were 100% similar among the spike protein. The 3D modeling of SARS-CoV-2 spike glycoprotein indicated that S protein has four domains with five protein units and the S1 subunit from 1 to 289 amino acid of domain 1 is highly conserved without any change in the ligand interaction site. This analysis clearly suggests that the S1 subunit (RBD 319–541) can be used as a target region for stable and safe vaccine development. Elsevier Ltd. 2022 2021-07-15 /pmc/articles/PMC8279943/ /pubmed/34307057 http://dx.doi.org/10.1016/j.matpr.2021.07.163 Text en © 2021 Elsevier Ltd. All rights reserved. Selection and peer-review under responsibility of the scientific committee of the Web International Conference on Accelerating Innovations in Material Science – 2020. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
S.N., Nagesha
B.N., Ramesh
C., Pradeep
K.S., Shashidhara
Ramakrishnappa, Thippeswamy
B.T., Krishnaprasad
S.M., Jnanashree
M., Manohar
N., Arunkumar
Yallappa
D., Dhanush Patel
T.V., Rakesh
E., Girish
Bagoji, Mahantesh
Chandaragi, Shreeram S.
SARS-CoV 2 spike protein S1 subunit as an ideal target for stable vaccines: A bioinformatic study
title SARS-CoV 2 spike protein S1 subunit as an ideal target for stable vaccines: A bioinformatic study
title_full SARS-CoV 2 spike protein S1 subunit as an ideal target for stable vaccines: A bioinformatic study
title_fullStr SARS-CoV 2 spike protein S1 subunit as an ideal target for stable vaccines: A bioinformatic study
title_full_unstemmed SARS-CoV 2 spike protein S1 subunit as an ideal target for stable vaccines: A bioinformatic study
title_short SARS-CoV 2 spike protein S1 subunit as an ideal target for stable vaccines: A bioinformatic study
title_sort sars-cov 2 spike protein s1 subunit as an ideal target for stable vaccines: a bioinformatic study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8279943/
https://www.ncbi.nlm.nih.gov/pubmed/34307057
http://dx.doi.org/10.1016/j.matpr.2021.07.163
work_keys_str_mv AT snnagesha sarscov2spikeproteins1subunitasanidealtargetforstablevaccinesabioinformaticstudy
AT bnramesh sarscov2spikeproteins1subunitasanidealtargetforstablevaccinesabioinformaticstudy
AT cpradeep sarscov2spikeproteins1subunitasanidealtargetforstablevaccinesabioinformaticstudy
AT ksshashidhara sarscov2spikeproteins1subunitasanidealtargetforstablevaccinesabioinformaticstudy
AT ramakrishnappathippeswamy sarscov2spikeproteins1subunitasanidealtargetforstablevaccinesabioinformaticstudy
AT btkrishnaprasad sarscov2spikeproteins1subunitasanidealtargetforstablevaccinesabioinformaticstudy
AT smjnanashree sarscov2spikeproteins1subunitasanidealtargetforstablevaccinesabioinformaticstudy
AT mmanohar sarscov2spikeproteins1subunitasanidealtargetforstablevaccinesabioinformaticstudy
AT narunkumar sarscov2spikeproteins1subunitasanidealtargetforstablevaccinesabioinformaticstudy
AT yallappa sarscov2spikeproteins1subunitasanidealtargetforstablevaccinesabioinformaticstudy
AT ddhanushpatel sarscov2spikeproteins1subunitasanidealtargetforstablevaccinesabioinformaticstudy
AT tvrakesh sarscov2spikeproteins1subunitasanidealtargetforstablevaccinesabioinformaticstudy
AT egirish sarscov2spikeproteins1subunitasanidealtargetforstablevaccinesabioinformaticstudy
AT bagojimahantesh sarscov2spikeproteins1subunitasanidealtargetforstablevaccinesabioinformaticstudy
AT chandaragishreerams sarscov2spikeproteins1subunitasanidealtargetforstablevaccinesabioinformaticstudy